-
US woman who survived botched execution is awake and speaking
-
Russia's plague scare: What we know
-
From 1800s to modern pharma: a Nobel-winning chemistry quest
-
French luxury giant to fund redevelopment of two Paris streets: city hall
-
Southampton boss Eckert given suspended ban over 'Spygate'
-
Trump wants to turn Florida golf course into presidential retreat
-
Russia warns of 'false' information as second plague case reported
-
Mayor of Turkish opposition stronghold defects to Erdogan party
-
IEA ready to release more oil reserves if necessary
-
Children among heavy casualties in Ukraine after Russian strikes
-
HSBC 'consults' over UK unit job cuts amid AI adoption
-
Court orders German ex-spy chief kept in jail after spying, treason arrest
-
UK court quashes five ex-traders' Libor rate rigging convictions
-
Guinea caps bottled water prices after sachets banned
-
XM Receives “Global Customer Experience Leader Award 2026” at the TrustFinance Performance Awards
-
Spared, married, hanged: the last weeks of Iranian protester Alireza Sepahi
-
Stocks slide as oil climbs on Mideast flareup
-
Nobel physics winner's pride at pioneering AI role
-
Heavy casualties in Ukraine after Russian strikes
-
IMF preparing El Nino assistance, concerned about AI bubble burst: chief to AFP
-
French wine harvest set to hit historic low
-
West must embrace 'national power' or face decline: Rubio
-
Kyiv 'cannot agree' to EU membership limiting food exports: minister
-
Shell refining margins reach record highs as wars hit supply
-
Arteta targets more Arsenal glory after signing new deal until 2030
-
Former Spain, Barca winger Pedro retires from football
-
Russell hit with Singapore grid penalty for taking new power unit
-
Arteta signs new Arsenal deal until 2030
-
Spotify expands audiobooks to more than 180 markets
-
Stocks decline as oil climbs on Mideast flareup
-
French-Japanese duo wins chemistry Nobel for solving molecular 'mystery'
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
G.AbuGhazaleh--SF-PST